Karyopharm Therapeutics (KPTI) EPS (Weighted Average and Diluted) (2020 - 2025)
Karyopharm Therapeutics (KPTI) reported EPS (Weighted Average and Diluted) of -$7.0 for Q4 2025, down 94.44% on a YoY basis from -$126.0 in Q4 2024, and down 83.25% quarter-over-quarter from -$3.82 in Q3 2025.
Karyopharm Therapeutics (KPTI) EPS (Weighted Average and Diluted) (2020 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$7.0 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 94.44% year-over-year to -$7.0; the trailing twelve-month figure through Dec 2025 stood at -$17.91 (down 17.29% YoY), and the FY2025 full-year result was -$17.93, down 28.07% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at -$7.0, down from -$3.82 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.52 in Q4 2021, with the low at -$17.9 in Q4 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$2.89 across 5 years, with a median of -$0.71 in 2021.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) tumbled 4161.9% — and 2024, when it jumped 79.89%.
- Karyopharm Therapeutics' EPS (Weighted Average and Diluted) stood at $0.52 in 2021, then sank by 180.77% to -$0.42 in 2022, then plunged by 4161.9% to -$17.9 in 2023, then jumped by 79.89% to -$3.6 in 2024, then tumbled by 94.44% to -$7.0 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$7.0 (Q4 2025), -$3.82 (Q3 2025), and -$4.32 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | -7.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.00 |
| Sep 30, 2025 | -3.82 |
| Jun 30, 2025 | -4.32 |
| Mar 31, 2025 | -2.77 |
| Dec 31, 2024 | -3.60 |
| Sep 30, 2024 | -3.85 |
| Jun 30, 2024 | -2.97 |
| Mar 31, 2024 | -4.85 |
| Dec 31, 2023 | -17.90 |
| Sep 30, 2023 | -0.30 |
| Jun 30, 2023 | -0.29 |
| Mar 31, 2023 | -0.30 |
| Dec 31, 2022 | -0.42 |
| Sep 30, 2022 | -0.45 |
| Jun 30, 2022 | -0.62 |
| Mar 31, 2022 | -0.53 |
| Dec 31, 2021 | 0.52 |
| Sep 30, 2021 | -0.69 |
| Jun 30, 2021 | -0.71 |
| Dec 31, 2020 | 1.60 |